Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to Buy
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Krystal Biotech, Inc. (KRYS), which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Krystal Biotech, Inc. Currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?
Let's discuss some of the components of the Momentum Style Score for KRYS that show why this company shows promise as a solid momentum pick.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For KRYS, shares are up 0.52% over the past week while the Zacks Medical - Biomedical and Genetics industry is down 0.45% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 28.58% compares favorably with the industry's 0.68% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Krystal Biotech, Inc. Have risen 18.62%, and are up 136.48% in the last year. In comparison, the S&P 500 has only moved 6.14% and 15.77%, respectively.
Investors should also take note of KRYS's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, KRYS is averaging 148,063 shares for the last 20 days.
The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with KRYS.
Over the past two months, 5 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost KRYS's consensus estimate, increasing from -$1.47 to -$1.25 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been 2 downward revisions in the same time period.
Taking into account all of these elements, it should come as no surprise that KRYS is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Krystal Biotech, Inc. On your short list.
Click to get this free report
Krystal Biotech, Inc. (KRYS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.